top of page

Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer

  • bgtaylor1
  • Nov 18, 2024
  • 2 min read

Logo for the National Institutes of Health

Date:

21 May 2024

PMID:

37907729

Category:

N/A

Authors:

Joakin O Mori, Isra Elhussin, W Nathaniel Brennen, Mindy K Graham, Tamara L Lotan, Clayton C Yates, Angelo M De Marzo, Samuel R Denmeade, Srinivasan Yegnasubramanian, William G Nelson, Gerald V Denis, Elizabeth A Platz, Alan K Meeker, Christopher M Heaphy

Abstract:


The stromal component of the tumour microenvironment in primary and metastatic prostate cancer can influence and promote disease progression. Within the prostatic stroma, fibroblasts are one of the most prevalent cell types associated with precancerous and cancerous lesions; they have a vital role in the structural composition, organization and integrity of the extracellular matrix. Fibroblasts within the tumour microenvironment can undergo cellular senescence, which is a stable arrest of cell growth and a phenomenon that is emerging as a recognized hallmark of cancer. Supporting the idea that cellular senescence has a pro-tumorigenic role, a subset of senescent cells exhibits a senescence-associated secretory phenotype (SASP), which, along with increased inflammation, can promote prostate cancer cell growth and survival. These cellular characteristics make targeting senescent cells and/or modulating SASP attractive as a potential preventive or therapeutic option for prostate cancer.


Acknowledgements:

The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute, or the National Institute of Health.


The Translational and Basic Science Research in Early Lesions (TBEL) Research Consortia is supported and funded by grants from the National Cancer Institute and the National Institutes of Health under the following award numbers:


Project Number:

Awardee Organization

U54CA274374

Fred Hutchinson Cancer Center

U54CA274375

Houston Methodist Research Institute

U54CA274370

Johns Hopkins University

U54CA274371

UT MD Anderson Cancer Center

U54CA274367

Vanderbilt University Medical Center


Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page